“ We expect a sea change in Indian biotech landscape ”
In an exclusive interaction with BioVoice eMag , Aditya Sharma , Head-Bioprocessing Business , Merck Life Science India shared his insights on the Indian biotech sector and how his company ’ s MLab initiative is enabling stakeholders . Do read his interesting views on the impact made by the life science industry during covid-19 pandemic .
BY RAHUL KOUL
Please take us through the idea behind the MLab and its journey so far ?
MLab Collaboration Center in Bangalore completed its five years of successful operations in April this year . The Centre highlights Merck ’ s world-class technical and application expertise . It is a non- GMP facility , equipped and designed to showcase technologies , recreate manufacturing environments , evaluate , troubleshoot processes and provide hands-on and virtual training . The Bangalore facility was started with a goal to nurture an environment where biopharmaceutical manufacturers could closely collaborate with Merck scientists and engineers in developing new therapies . Customers were able to get firsthand knowledge and experience to optimise their manufacturing processes and make breakthroughs in technologies targeted to solve toughest of health challenges .
What is the purpose of the MLab Collaboration Center and how is it helping in solving complex problems ?
MLab Collaboration Centre in Bengaluru is managed by a team of experts , scientists and engineers with global expertise
Aditya Sharma is a senior professional and an accomplished business leader with an in-depth knowledge of the Indian Life Sciences Industry . With a strong business acumen and strategic thinking , he has had a diverse career of over two decades in roles with differing complexities and challenges .
22
BioVoiceNews | October 2022